In July 2019, Amgen’s Kanjinti (trastuzumab biosimilar) and Mvasi (bevacizumab biosimilar) were the first monoclonal antibody (MAb) biosimilars launched in the United States. Between mid-2018 and early-2019, trastuzumab biosimilars (Herzuma, Ontruzant, Kanjinti, Trazimera, and Ogivri) expanded the biosimilar sector of the European oncology market. Uptake of these MAb biosimilars and biosimilars of granulocyte colony-stimulating factor (G-CSF) and erythropoiesis-stimulating agent (ESA) biosimilars will depend on the prescribing behavior of oncologists. To help manufacturers/marketers of oncology biosimilars and brands understand the opinions, actions, and expectations of these physicians, Decision Resources Group has conducted primary market research with oncologists in France, Germany, and the United States on the use of branded drugs versus their biosimilar competitors.
- What is the current patient share of oncology biosimilars, and what expectations do oncologists have for future patient shares, assuming additional biosimilars launch?
- How similar do oncologists believe biosimilars are to their reference brands?
- What factors do oncologists identify as being the key drivers and barriers to biosimilar uptake?
- What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
- What cost reduction is required for a biosimilar to achieve more than a 50% patient share?
Key markets covered:
- United States
Key companies mentioned:
- Accord Healthcare
- Bristol-Myers Squibb
Key drugs mentioned:
- Current Treatment: Biosimilars Oncology Report 2019
Author(s): Jimmy Jacob
Jimmy Jacob, is a Business Insights Analyst in the Biosimilars team. Prior to joining DRG, Jimmy worked as a Scientist in Medimmune and Horizon Discovery mostly involving CRIPSR/Cas9 therapeutics. He received his master’s degree in Biotechnology from University of Dundee and his from Imperial College London. His work involved identifying novel molecules that regulated oestrogen receptor-alpha in breast cancer.